Pardes Biosciences, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 57
- Market Cap
- -
- Website
- https://www.pardesbio.com
PBI-0451 (Pomotrelvir) Phase 2 Study in Nonhospitalized Symptomatic Adults With COVID-19
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Pardes Biosciences, Inc.
- Target Recruit Count
- 242
- Registration Number
- NCT05543707
- Locations
- 🇺🇸
Voyage Medical, Mesa, Arizona, United States
🇺🇸Franco A Felizarta MD, Bakersfield, California, United States
🇺🇸Allianz Research Institute - Colorado, Westminster, California, United States
Study of PBI-0451 in Healthy Subjects.
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Pardes Biosciences, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT05011812
- Locations
- 🇳🇿
Auckland City Hospital, Auckland, New Zealand
© Copyright 2024. All Rights Reserved by MedPath